GRTX

Galera Therapeutics Inc

GRTX, USA

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy that is in Phase 2a clinical trial. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

https://www.galeratx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GRTX
stock
GRTX

Galera (OTC: GRTX) to sell dismutase mimetics to Biossil; $3.5M upfront, up to $105M Stock Titan

Read more →
GRTX
stock
GRTX

Galera Therapeutics Sells Assets to Biossil Inc. The Globe and Mail

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$0.5

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.01

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

0.93 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-27.75 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 1.75% of the total shares of Galera Therapeutics Inc

1.

abrdn Healthcare Opportunities

(0.5781%)

since

2024/09/30

2.

abrdn Healthcare Investors

(0.545%)

since

2024/10/31

3.

abrdn World Healthcare

(0.2973%)

since

2024/09/30

4.

abrdn Life Sciences Investors

(0.2312%)

since

2024/10/31

5.

XTX Topco Ltd

(0.0958%)

since

2024/06/30

6.

State Street Corp

(0%)

since

2024/06/30

8.

Atom Investors LP

(0%)

since

2024/06/30

9.

Wells Fargo & Co

(0%)

since

2024/06/30

10.

Jane Street Group LLC

(0%)

since

2024/06/30

11.

Northern Trust Corp

(0%)

since

2024/06/30

12.

Millennium Management LLC

(0%)

since

2024/06/30

14.

U.S. Bancorp

(0%)

since

2024/06/30

15.

Good Life Advisors, LLC

(0%)

since

2024/06/30

16.

GSA Capital Partners LLP

(0%)

since

2024/06/30

17.

Kestra Advisory Services, LLC

(0%)

since

2024/06/30

18.

abrdn PLC

(0%)

since

2024/06/30

19.

HRT FINANCIAL LLC

(0%)

since

2024/06/30

20.

Parallel Advisors, LLC

(0%)

since

2024/06/30

21.

Royal Bank of Canada

(0%)

since

2024/06/30

22.

Summit Trail Advisors, LLC

(0%)

since

2024/06/30

23.

J.W. COLE ADVISORS, INC.

(0%)

since

2024/06/30

24.

Level Four Advisory Services, LLC

(0%)

since

2024/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.01

EPS Estimate

0

EPS Difference

-0.01

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(1)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

Galera Therapeutics Inc (GRTX) Stock Details & Analysis - Finnton | Finnton